You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY21 is not expected to be complete until September, 2022.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

  1. Marburg Virus Prophylactic Medical Countermeasure

    SBC: MAPP BIOPHARMACEUTICAL, INC.            Topic: CBD18A002

    There are currently no vaccines or therapeutics available for Marburg Virus Disease (MVD). Given the specter of weaponization and the terriblemorbidity and high mortality rate of MVD, this represents a critical threat to the operational readiness of the Warfighter. While traditionalvaccines have proven to be a huge contribution to public health, they do have some limitations especially in the cont ...

    STTR Phase I 2018 Department of DefenseOffice for Chemical and Biological Defense
  2. Marburg Virus Prophylactic Medical Countermeasure

    SBC: Flow Pharma, Inc.            Topic: CBD18A002

    Flow Pharma, Inc. is a biotechnology company in the San Francisco Bay Area developing fully synthetic cytotoxic T lymphocyte (CTL)stimulating peptide vaccines for Marburg virus. The FlowVax vaccine platform allows us to create dry powder formulations of biodegradablemicrospheres and TLR adjuvants incorporating class I and class II T cell epitopes. FlowVax vaccines can be designed for delivery by i ...

    STTR Phase I 2018 Department of DefenseOffice for Chemical and Biological Defense
  3. Virus-Like Particle Based pan-Marburgvirus Vaccine

    SBC: Luna Innovations Incorporated            Topic: CBD18A002

    Marburg virus (MARV) is a filamentous enveloped non-segmented negative sense RNA virus. This viruse is considered to be extremelydangerous with case fatality rates as high as 88-90%. Extensive efforts have gone towards effective vaccines for MARV prevention, however,none have been successfully established as licensed vaccines. Glycoprotein (GP) is the only surface protein of MARV. There are substa ...

    STTR Phase I 2018 Department of DefenseOffice for Chemical and Biological Defense
  4. STTR Phase II: Novel Analysis Tools for Production of Higher Indican Yielding Plants for Bio-based Indigo

    SBC: STONY CREEK COLORS, INC.            Topic: CT

    This Small Business Technology Transfer (STTR) Phase II project will develop a new tool for the analysis of in situ indican precursor in indigo plants, which when combined with genomic analysis and genetic linkage mapping in selectively bred indigo crops, will lead to high indican yielding breeding parental lines and ultimately competitively price natural indigo dye. Additionally, characterization ...

    STTR Phase II 2018 National Science Foundation
  5. STTR Phase II: Occupancy Estimation and Energy Savings with True Presence Sensors

    SBC: ADNOVIV, INC.            Topic: EW

    The broader impact/commercial potential of this project will extend to a number of applications, including smart buildings, home automation, and security. The development of this new technology for efficient indoor sensing, and development of new algorithms for occupancy sensing and counting techniques, will have immediate implications in the building automation and home construction industries, w ...

    STTR Phase II 2018 National Science Foundation
  6. STTR Phase II: HI-LIGHT- Solar Thermal Chemical Reactor Technology for Converting CO2 to Hydrocarbons

    SBC: Dimensional Energy Inc.            Topic: CT

    The broader impact/commercial potential of this STTR Phase II project will result in significant economic activity through the utilization of waste carbon dioxide. The photo-catalytic reactors funded in the project will lead to novel methods to chemically store energy from the sun. Each year, human activity releases 38 billion tons of carbon dioxide into the atmosphere. Dimensional Energy envision ...

    STTR Phase II 2018 National Science Foundation
  7. STTR Phase II: Self-Health Management Informatics Platform: Improving Patient Engagement in Care Delivery

    SBC: SIPPA Solutions LLC            Topic: SH

    The broader impact/commercial potential of this Small Business Technology Transfer (STTR) Phase II project is a patient-centric engagement process that offers the best chance for enabling a scalable approach towards achieving the triple aim of improving care quality and outcomes, controlling health care costs and utilization, and increasing patient satisfaction. Currently the national healthcare c ...

    STTR Phase II 2018 National Science Foundation
  8. STTR Phase I: Manganese Oxide-Carbon Nanosheet Anodes for Extreme High Power Lithium Ion Batteries

    SBC: EnerMat Technologies, Inc.            Topic: CT

    The broader impact/commercial potential of this Small Business Technology Transfer (STTR) project is the advancement of improved lithium ion batteries. The project will evaluate new battery chemistry enabling more rapid charging rates then currently available in the worldwide energy storage marketplace. Such high power density batteries would cater to a major emerging battery segment where current ...

    STTR Phase I 2018 National Science Foundation
  9. STTR Phase I: A Mobile Triage Application for Reducing the Risk of COPD Exacerbations

    SBC: REVON SYSTEMS, INC            Topic: SH

    The broader impact/commercial potential of this Small Business Technology Transfer (STTR) project is the reduction of significant disease flare-ups in patients with Chronic Obstructive Pulmonary Disease (COPD), increase in patient quality-of-life, and a reduction of expensive and unnecessary healthcare utilization. Current at-home care support for COPD patients is often completely missing or consi ...

    STTR Phase I 2018 National Science Foundation
  10. STTR Phase I: Hemodynamic Effects Inform Design of an External Stent to Reduce Dialysis Access Failures

    SBC: VenoStent, Inc.            Topic: BM

    The broader impact/commercial potential of this Small Business Technology Transfer (STTR) project is to develop an external stent that can improve the quality and length of life for dialysis patients. Dialysis is the primary lifeline for End-Stage Renal Disease patients. Unfortunately, our current standard of care, which provides no additional support or treatment to the artery-vein connections su ...

    STTR Phase I 2018 National Science Foundation
US Flag An Official Website of the United States Government